Stifel Maintains Buy on Apogee Therapeutics, Raises Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Akash Tewari has maintained a Buy rating on Apogee Therapeutics (NASDAQ:APGE) and increased the price target from $46 to $95.
March 05, 2024 | 6:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Akash Tewari reaffirmed a Buy rating on Apogee Therapeutics and raised the price target to $95 from $46.
The increase in price target by a reputable analyst suggests a strong confidence in Apogee Therapeutics' future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100